RecruitingGlaucoma
Topical Insulin for Glaucoma
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Sponsor: Stanford University
You may qualify if…
- ✓ Capable to provide informed consent
- ✓ Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
- ✓ Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.
You may not qualify if…
- ✕ Pregnant or breastfeeding woman
- ✕ Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
- ✕ Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
- ✕ Inability to perform reliable visual field
- ✕ Unable to provide informed consent
- ✕ Unable to complete the tests and follow-ups required by the study
Where it's recruiting
California
Palo Alto
Source: ClinicalTrials.gov · NCT05206877 · last updated 2026-10-20